Amivantamab
Amivantamab
not stated in source · Single arm
ACC (n = 21)
median progression-free survival: 4.6 months, results posted 05.08.2026
Amivantamab in ACC · NCT05074940
ACC
Programs, trials, and reported response and survival for adenoid cystic carcinoma.
ACC pipeline
Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.
10 arms have a reported figure in this set.
Amivantamab
not stated in source · Single arm
ACC (n = 21)
median progression-free survival: 4.6 months, results posted 05.08.2026
Amivantamab in ACC · NCT05074940
Axitinib 5 mg twice daily
5 mg · ITT
R/M ACC with progression within 9 months (n = 60 total)
Comparator: observation
median progression-free survival: 10.8 months, primary analysis
6-month progression-free survival: 73%, 6 months
Axitinib vs observation (randomized Phase 2) · NCT02859012
Observation
none · ITT
R/M ACC with progression within 9 months
median progression-free survival: 2.8 months, primary analysis
6-month progression-free survival: 23%, 6 months
Axitinib vs observation (randomized Phase 2) · NCT02859012
Axitinib + avelumab
axitinib 5 mg twice daily + avelumab · Single arm
R/M ACC (n = 28 evaluable)
median progression-free survival: 7.3 months, primary analysis
Axitinib + avelumab, ACC-I subtype
as above · Single arm
ACC-I (exploratory biomarker analysis of 28 patients)
median progression-free survival: 1.8 months, updated analysis; exploratory
Axitinib + avelumab, ACC-II subtype
as above · Single arm
ACC-II (exploratory)
median progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-I
Emi-Le, post hoc aggressive subtype
Phase 1 doses (not stated in source) · Single arm
ACC with solid histology or high-grade transformation (n = 32, post hoc)
median progression-free survival: 7.8 months, ASCO 2026; post hoc
Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort) · NCT05377996
Lenvatinib 24 mg
24 mg · Single arm
progressive R/M ACC (n = 32 evaluable)
median progression-free survival: 17.5 months, 8 progression events
Lenvatinib MSK Phase 2 · NCT02780310
Lenvatinib 24 mg
24 mg · Single arm
R/M salivary ACC (n = 26 evaluable)
median progression-free survival: 9.1 months, primary analysis
ACC-LEN14 · NCT02860936
Rivoceranib 700 mg
700 mg · Single arm
R/M ACC (n = 80; 72 evaluable)
median progression-free survival: 9 months, primary analysis
Rivoceranib Phase 2 · NCT04119453
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.